Handelsavisen
prelaunch
Companies ›Healthcare ›6872.TWO
68
6872.TWO — TPEx Advanced Medical Equipment & Technology

NaviFUS Corp

$18,00
Open in Charts → Attach watcher ⌖
— —
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,3B TWD
P/E
—
EV / Rev
95,1x
Div yield
0,00 %
Op margin
—
ROE
-3,9 %
Net margin
—
Debt / equity
0,06
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

NaviFUS Corp develops and commercializes advanced medical equipment and technology, focusing on innovative healthcare solutions.

Business. NaviFUS Corp (6872.TWO) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is listed on the Taiwan Premium Board (TPEx) and focuses on the development and sale of advanced medical equipment. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-3,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6872.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6872.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    NaviFUS Corp (6872.TWO) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is listed on the Taiwan Premium Board (TPEx) and focuses on the development and sale of advanced medical equipment. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    NaviFUS Corp maintains a strong liquidity position with $307.2 million in cash and equivalents, representing 48.4% of total assets. The company's liquidity FPT score indicates a low liquidity risk, supported by a current ratio of 11.21 and a debt-to-equity ratio of 0.06. Despite this, the company reported negative free cash flow of -$43.9 million, driven by capital expenditures of -$26.4 million.

    Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of -$21.6 million, with a return on equity of -3.91% and a return on assets of -3.4%. These figures indicate operational inefficiencies and a lack of asset utilization effectiveness, which are critical concerns for a company in the capital-intensive medical equipment industry.

    Geographic and segment exposure data is not available in the current dataset, but the company's revenue concentration remains a potential risk factor. The absence of disclosed segments or geographic breakdowns limits visibility into diversification strategies.

    Growth trajectory analysis reveals a challenging outlook. The company reported zero revenue in the latest period, with no historical revenue data provided to assess growth trends. The lack of revenue generation combined with significant operating losses suggests a high risk of continued financial strain in the near term.

    Risk assessment highlights low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating income of -$25.9 million and net loss of -$21.6 million raise concerns about long-term sustainability. The absence of dilution pressure is a positive, but the company's capital structure remains vulnerable to market volatility.

    Recent events and filings do not show any material developments in the last quarter. The company has not disclosed any significant strategic shifts, product launches, or regulatory changes that could impact its financial trajectory.

    Key takeaways
    • NaviFUS Corp has a strong liquidity position with $307.2 million in cash and equivalents, but negative free cash flow raises concerns about operational efficiency.
    • The company is reporting significant losses, with a net loss of -$21.6 million and a return on equity of -3.91%, indicating poor profitability.
    • No revenue was reported in the latest period, and historical revenue data is unavailable, making it difficult to assess growth potential.
    • The company has low liquidity and dilution risk, but its capital structure and operational performance remain a concern.
    • No recent strategic or operational developments have been disclosed, limiting visibility into future direction.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 2

    The company maintains a low debt-to-equity ratio of 0.06, matching the cohort median and suggesting manageable leverage levels.

    Dilution and liquidity risks are assessed as low, providing a stable capital structure environment for potential recovery.

    BEAR CASE · 2

    The company faces high credit risk, raising concerns about its ability to meet financial obligations amidst ongoing losses.

    Cash conversion ratio of -0.09 places NaviFUS in the bottom quartile of its cohort, indicating poor cash generation capability.

    In focus — financials by report

    Valuation FY

    Market price
    $18,00
    Market cap
    $1.27B
    Enterprise valueⓘ
    $997.3M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    95.1x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    487.7x
    P / Bⓘ
    2.3x
    P / Tangible bookⓘ
    2.3x
    Tangible book
    $552.5M
    Net cashⓘ
    $276.2M
    Current ratioⓘ
    11.2
    Debt / equityⓘ
    0.1
    ROAⓘ
    -3.4%
    ROEⓘ
    -3.9%
    Cash conversionⓘ
    -9.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-3,9 %Below median
    D/E0,06Above median
    Cash Conv-0,09Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • NaviFUS Corp Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6872.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage